MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS

雌激素提高血浆 APO A1 水平的机制

• 批准号: 6304531
• 负责人: ERNST JOHN SCHAEFER
• 金额: $ 4.27万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304531
• 关键词: apolipoproteins; blood lipoprotein metabolism; clinical research; coronary disorder; disease /disorder proneness /risk; estrogens; female; hormone regulation /control mechanism; hormone therapy; human subject; human therapy evaluation; medroxyprogesterone; postmenopause

Postmenopausal women are at higher risk of coronary heart disease (CHD) than premenopausal women, even after controlling for age-effects. However, estrogen replacement therapy significantly lowers the risk of CHD in postmenopausal women. With this study, we propose to determine the kinetics of apolipoprotein A-I, the major protein component of high density lipoproteins, in postmenopausal women undergoing a placebo-controlled, randomized treatment with each of the following regimens:a)placebo,b)0.625mg/d conjugated estrogens, and c)0.625mg/d conjugated estrogens.

绝经后妇女患冠心病（CHD）的风险高于绝经前妇女，即使在控制年龄影响后也是如此。然而，雌激素替代疗法显著降低绝经后妇女冠心病的风险。在这项研究中，我们建议确定载脂蛋白a - i（高密度脂蛋白的主要蛋白质成分）的动力学，绝经后妇女接受安慰剂对照，随机治疗以下方案：a)安慰剂，b)0.625mg/d结合雌激素，c)0.625mg/d结合雌激素。